Literature DB >> 18450803

Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.

O Plan1, G Cambonie, E Barbotte, P Meyer, C Devine, C Milesi, O Pidoux, M Badr, J C Picaud.   

Abstract

BACKGROUND: Intermittent infusion of vancomycin is widely used to treat late-onset sepsis in neonates. On the other hand, the continuous infusion of vancomycin could improve bactericidal efficacy since its action is time dependent.
OBJECTIVE: To evaluate a simplified dosage schedule for continuous-infusion vancomycin therapy.
METHODS: Prospective study in premature neonates (<34 weeks) with suspected coagulase-negative staphylococci (CoNS) sepsis. Before antibiotics at time zero (T0), serum creatinine was measured and blood cultures were collected. Vancomycin dosage began with 25 mg/kg/day or 15 mg/kg/day (period 1) and 30 mg/kg/day or 20 mg/kg/day (period 2) depending on whether serum creatinine was below or above 90 mumol/l. Two days after beginning treatment (first timepoint: T1), serum vancomycin was measured and second blood cultures were collected.
RESULTS: Between June 2002 and December 2005, 145 neonates were evaluated. At birth, the median (interquartile range) body weight was 920 (500-1160) g and gestational age was 28 (26-29) weeks. At T1, serum vancomycin was within the required range in 74.5% of neonates (108/145). Serum vancomycin levels were higher in period 2 than in period 1 (20 mg/l vs 13 mg/l, p<0.05). At T0, 55% (80/145) of blood cultures were positive for CoNS, but 71% (57/80) were negative at T1. Four days after beginning treatment, 92% of subjects had recovered without removing the central venous catheter.
CONCLUSION: Using this simplified dosage schedule, bactericidal efficacy was maintained and most subjects had serum vancomycin concentrations within the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18450803     DOI: 10.1136/adc.2007.128280

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  10 in total

1.  Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.

Authors:  Julianne Kim; Sandra A N Walker; Dolores C Iaboni; Scott E Walker; Marion Elligsen; Michael S Dunn; Vanessa G Allen; Andrew Simor
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

2.  Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.

Authors:  Federico Pea; Mario Furlanut; Camilla Negri; Federica Pavan; Massimo Crapis; Francesco Cristini; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 3.  Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.

Authors:  Heather L Girand
Journal:  J Pediatr Pharmacol Ther       Date:  2020

4.  Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.

Authors:  Esther J H Janssen; Pyry A J Välitalo; Karel Allegaert; Roosmarijn F W de Cock; Sinno H P Simons; Catherine M T Sherwin; Johan W Mouton; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

5.  Optimization of vancomycin dosing in very low-birth-weight preterm neonates.

Authors:  Theresa Madigan; Christine B Teng; Jena Koshaish; Kent R Johnson; Kevin K Graner; Ritu Banerjee
Journal:  Am J Perinatol       Date:  2014-05-16       Impact factor: 1.862

Review 6.  Clinical pharmacokinetics of vancomycin in the neonate: a review.

Authors:  Gian Maria Pacifici; Karel Allegaert
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

7.  Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial.

Authors:  Amanda Gwee; Noel Cranswick; Susan M Donath; Rodney Hunt; Nigel Curtis
Journal:  BMJ Open       Date:  2018-11-03       Impact factor: 2.692

8.  Assessment of vancomycin utilization among Lebanese hospitals.

Authors:  Diana N Malaeb; Iqbal M Fahs; Pascale Salameh; Souheil Hallit; Manal Saad; Jassem Bourji; Rabih Hallit
Journal:  Saudi Med J       Date:  2019-02       Impact factor: 1.484

Review 9.  Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review.

Authors:  Marta Mejías-Trueba; Marta Alonso-Moreno; Laura Herrera-Hidalgo; Maria Victoria Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2021-03-25

10.  Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?

Authors:  Roberta Maia de Castro Romanelli; Lêni Márcia Anchieta; Juliana Chaves Abreu Fernandes; Mariana Antunes Faria Lima; Taís Marina de Souza; Viviane Rosado; Wanessa Trindade Clemente; Paulo Augusto Moreira Camargos
Journal:  Braz J Infect Dis       Date:  2016-08-12       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.